<DOC>
	<DOCNO>NCT00796055</DOCNO>
	<brief_summary>To determine safety , tolerability , high dose drug give every 3 week every week , ( per 21 day cycle ) adult subject relapse refractory solid tumor .</brief_summary>
	<brief_title>Study MEDI-547 Evaluate Safety , Tolerability , Biologic Activity IV Administration Subjects With Relapsed Refractory Solid Tumors</brief_title>
	<detailed_description>To determine safety , tolerability , maximum tolerate dose ( MTD ) MEDI 547 dose escalation cohort either administration schedule 1 dose every 3 week 1 dose every week adult subject relapse refractory solid tumor .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For doseescalation cohort : cancer relapse refractory least 1 prior standard care systemic regimen standard therapy previous histological confirmation diagnosis fallopian tube , primary peritoneal , endometrial , cervical , prostate , nonsmall cell lung , esophageal , gastric , bladder , renal cell carcinoma melanoma . Subjects relapse refractory breast , epithelial ovarian , colon cancer previous histological confirmation diagnosis must progress 1 prior regimen therapy . For patient enrol NCI , pathology must confirm Department Pathology , CCR , NCI . For doseexpansion cohort : relapsed refractory epithelial ovarian cancer progression 1 prior regimen therapy , relapse refractory fallopian tube , primary peritoneal cancer progression least 1 prior standard care systemic regimen , previous histological confirmation cancer diagnosis . For patient enrol NCI , pathology must confirm Department Pathology , Center Cancer Research ( CCR ) , NCI . Patients follow histologic epithelial ovarian cancer cell type eligible : Serous adenocarcinoma , endometrioid adenocarcinoma , mucinous adenocarcinoma , undifferentiated carcinoma , clear cell adenocarcinoma , mixed epithelial carcinoma , transitional cell carcinoma , malignant Brenner 's Tumor , adenocarcinoma otherwise specify ( NOS ) . For doseexpansion cohort subject relapse refractory ovarian cancer , subject must archival tumor sample demonstrate EphA2 expression immunohistochemical stain . Males female least 18 year age time obtain informed consent . Women childbearing potential must negative serum pregnancy test within 72 hour prior MEDI547 administration ; men woman reproductive potential must agree practice effective method avoid pregnancy ( include oral implant contraceptive ( `` pill '' , `` patch '' , Depo Provera shot , hormone lace intrauterine device , allow follow : non hormonal ( copper ) , intrauterine device , female condom , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner sterile sexual partner ) beginning time ICF sign , must agree continue use precaution receive MEDI547 30 day last dose MEDI547 . For doseescalation cohort : measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) criterion desirable require . The following consider measurable : pleural effusion ascites ; osteoblastic/osteoclastic lesion evidence disease bone scan alone ; progressive irradiated lesion alone , bone marrow involvement , brain metastasis , malignant hepatomegaly physical exam alone ; chemical marker ( eg , CA125 , carcinoembryonic antigen [ CEA ] , prostate specific antigen [ PSA ] ) . Recurrent disease follow surgery radiotherapy measurable provide 30 day elapse since treatment measurable disease exists outside radiation port , clear progression within radiation port . For doseexpansion cohort : measurable disease , RECIST criterion require . The following consider measurable : pleural effusion ascites ; osteoblastic/osteoclastic lesion evidence disease bone scan alone ; progressive irradiated lesion alone , bone marrow involvement , brain metastasis , malignant hepatomegaly physical exam alone ; chemical marker ( eg , CA125 , CEA , PSA ) . Recurrent disease follow surgery radiotherapy measurable provide 30 day elapse since treatment measurable disease exists outside radiation port , clear progression within radiation port . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . Life expectancy great 16 week . For subject prior treatment chemotherapy , biological therapy , radiotherapy , investigational therapy prior surgery : eligible study entry least 30 day pass since treatment/surgery , provide toxicity related prior treatment resolve ≤ Grade 1 severity National Cancer Institute Common Terminology Criteria Adverse Events version 3.0 ( NCI CTCAE v3.0 surgical wound heal . Prior immunotherapy approve agent ( eg , trastuzumab , cetuximab , panitumumab , bevacizumab ) allowable least 30 day pass . Absolute neutrophil count ( ANC ) ³ 1500/mm3 , platelet ³ 100,000/mm3 , hemoglobin &gt; 10.0 g/dL , serum creatinine great equal 1.5 time upper limit normal [ ULN ] calculate creatinine clearance &gt; 50 mL/min , serum bilirubin great equal 2 time ULN , alkaline phosphatase &lt; 3 time ULN , aspartate transferase ( AST ) alanine transferase ( ALT ) great equal 3 time ULN . Prothrombin time ( PT ) , partial thromboplastin time ( PTT ) , international normalize ratio ( INR ) within normal institutional limit . Written inform consent Health Insurance Portability Accountability Act ( HIPAA ) authorization ( applies cover entity USA ) obtain subject prior receipt study medication begin study procedure . Pregnant lactating woman . A history central nervous system metastases primary central nervous system tumor . Symptomatic pleural effusion ascites require paracentesis . Symptomatic peripheral neuropathy Grade 2 great . Respiratory insufficiency require oxygen treatment , lymphangitic involvement lung . Any evidence hematemesis , melena , hematochezia , grade 2 high hemoptysis , gross hematuria . Patients grade 1 hemoptysis microscopic hematuria permit study . Active recent history ( within 3 month ) keratitis conjunctivitis . A history significant adverse event relate previously administer monoclonal antibody . A history human immunodeficiency virus ( HIV ) hepatitis virus infection ( HBV , HCV ) exclude eliminate risk increase adverse event due immune compromise liver dysfunction . Any evidence history myocardial infarction , angina , arrhythmia ( include atrial fibrillation , multifocal premature ventricular contraction , ventricular bigeminy trigeminy , ventricular tachycardia requirement antiarrhythmic include digoxin ) , within 6 month prior initiation study drug . Any evidence uncontrolled hypertension ( systolic blood pressure &gt; 150 mm Hg ) within 3 month prior initiation investigational product . Subjects currently anticoagulant therapy thromboembolic disorder prophylactic reason exclude . Any evidence severe congestive heart failure severity New York Heart Association classification &gt; Class 1 within past 12 week . A marked baseline prolongation QTc interval ( eg , demonstration QTc interval ≥ 500 millisecs [ m ] ) . A prior stroke transient ischemic attack ( TIA ) within 6 month prior initiation ( investigational product ) MEDI547 . Any evidence active infection systemic use antimicrobial within 72 hour prior initial treatment MEDI547 . Current plan participation ( day study entry 30 day last dose study drug ) research protocol another investigational agent therapy may administer . Received another investigational agent within 30 day prior initiation study drug fully recover prior investigational treatment . A requirement palliative chemotherapy , hormonal therapy , radiotherapy , surgery , immunotherapy course study . For subject doseexpansion cohort , history prior malignancy within past 5 year nonmelanomatous skin cancer control , carcinoma situ cervix , superficial bladder cancer . A general medical psychological condition behavior , include substance dependence abuse , opinion investigator , might permit subject complete study sign inform consent . Any condition opinion investigator would interfere evaluation investigational product interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>